Fig. 5
From: Cerumenogram as an assay for the metabolic diagnosis of precancer, cancer, and cancer remission
(A) Cerumenogram longitudinal results for the volunteer. Three Cerumenogram analyses classified the sample as part of the oncological risk group; in the fourth analysis, the sample was classified as part of the oncological risk-free group. (B) 68Ga-PET-CT/PSMA confirmed a hypercapturing lymph node abnormality in the left external iliac lymph node, with SUVmax values of 7.6 and 17.6 g mL−1 in the early and delayed images, respectively. (C) Computed tomography (CT) images (iii) before and (iv) after treatment, showing complete remission of the lymph node.
